Endothelin receptor antagonist reduces markers of PCa

Chicago-The selective endothelin receptor antagonist atrasentan significantly attenuates changes in biochemical markers of bone metabolism and disease progression in a group of patients with advanced hormone-refractory prostate cancer that had progressed on placebo, according to the results of a randomized clinical trial.

Related Content:

Drug TherapyFemale Urology

FPMRS patients evaluate televisits through survey-based study

Evaluating the feasibility of telemedicine in a post-pandemic world

Investigators assess the satisfaction of telehealth visits in FPMRS patients